Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)

This consensus statement, conceived as a joint initiative of the Spanish Society of Pathology and the Spanish Society of Medical Oncology, makes diagnostic and treatment recommendations for the management of patients with hereditary, localised and advanced CRC based on the current scientific evidenc...

Full description

Saved in:
Bibliographic Details
Published inClinical & translational oncology Vol. 14; no. 10; pp. 726 - 739
Main Authors García-Alfonso, Pilar, Salazar, Ramón, García-Foncillas, Jesús, Musulén, Eva, García-Carbonero, Rocío, Payá, Artemio, Pérez-Segura, Pedro, Ramón y Cajal, Santiago, Navarro, Samuel
Format Journal Article
LanguageEnglish
Published Milan Springer Milan 01.10.2012
Subjects
Algorithms
Biomarkers, Tumor - analysis
Biomarkers, Tumor - genetics
Carcinoma - diagnosis
Carcinoma - genetics
Colorectal Neoplasms - diagnosis
Colorectal Neoplasms - genetics
Consensus
Diagnostic Techniques and Procedures
Humans
Medical Oncology - legislation & jurisprudence
Medical Oncology - organization & administration
Medicine
Medicine & Public Health
Microsatellite Instability
Oncology
Pathology, Clinical - legislation & jurisprudence
Pathology, Clinical - organization & administration
Practice Guidelines as Topic
Prognosis
Societies, Medical - legislation & jurisprudence
Societies, Medical - organization & administration
Spain
Special Article
Spain
PTEN
MSI
KRAS
BRAF
EGFR
Online AccessGet full text
ISSN1699-048X
1699-3055
1699-3055
DOI10.1007/s12094-012-0856-5

Cover

Abstract This consensus statement, conceived as a joint initiative of the Spanish Society of Pathology and the Spanish Society of Medical Oncology, makes diagnostic and treatment recommendations for the management of patients with hereditary, localised and advanced CRC based on the current scientific evidence on biomarker use. This consensus statement thus provides an opportunity to improve healthcare efficiency and resource use, which will benefit these patients. Based on the currently available data on this subject, this expert group recommends testing for microsatellite instability (MSI) in patients with localised CRC, as this is a strong predictive factor for deciding on adjuvant treatment. However, although the ColoPrint ® and Oncotype Dx ® gene expression signatures have been shown to have prognostic value, no consensus yet exists concerning their use in clinical practice. For advanced CRC, it is essential to test for KRAS mutation status before administering an anti-EGFR treatment, such as cetuximab or panitumumab. However, testing for other biomarkers, such as BRAF , EGFR , PI3K and PTEN mutations, should not be done routinely, because this does not influence treatment planning at the present time. Other important issues addressed include organisational requirements and the quality controls needed for proper testing of these biomarkers as well as the legal implications to be borne in mind when testing some biomarkers.
AbstractList This consensus statement, conceived as a joint initiative of the Spanish Society of Pathology and the Spanish Society of Medical Oncology, makes diagnostic and treatment recommendations for the management of patients with hereditary, localised and advanced CRC based on the current scientific evidence on biomarker use. This consensus statement thus provides an opportunity to improve healthcare efficiency and resource use, which will benefit these patients. Based on the currently available data on this subject, this expert group recommends testing for microsatellite instability (MSI) in patients with localised CRC, as this is a strong predictive factor for deciding on adjuvant treatment. However, although the ColoPrint(®) and Oncotype Dx(®) gene expression signatures have been shown to have prognostic value, no consensus yet exists concerning their use in clinical practice. For advanced CRC, it is essential to test for KRAS mutation status before administering an anti-EGFR treatment, such as cetuximab or panitumumab. However, testing for other biomarkers, such as BRAF, EGFR, PI3K and PTEN mutations, should not be done routinely, because this does not influence treatment planning at the present time. Other important issues addressed include organisational requirements and the quality controls needed for proper testing of these biomarkers as well as the legal implications to be borne in mind when testing some biomarkers.
This consensus statement, conceived as a joint initiative of the Spanish Society of Pathology and the Spanish Society of Medical Oncology, makes diagnostic and treatment recommendations for the management of patients with hereditary, localised and advanced CRC based on the current scientific evidence on biomarker use. This consensus statement thus provides an opportunity to improve healthcare efficiency and resource use, which will benefit these patients. Based on the currently available data on this subject, this expert group recommends testing for microsatellite instability (MSI) in patients with localised CRC, as this is a strong predictive factor for deciding on adjuvant treatment. However, although the ColoPrint(®) and Oncotype Dx(®) gene expression signatures have been shown to have prognostic value, no consensus yet exists concerning their use in clinical practice. For advanced CRC, it is essential to test for KRAS mutation status before administering an anti-EGFR treatment, such as cetuximab or panitumumab. However, testing for other biomarkers, such as BRAF, EGFR, PI3K and PTEN mutations, should not be done routinely, because this does not influence treatment planning at the present time. Other important issues addressed include organisational requirements and the quality controls needed for proper testing of these biomarkers as well as the legal implications to be borne in mind when testing some biomarkers.This consensus statement, conceived as a joint initiative of the Spanish Society of Pathology and the Spanish Society of Medical Oncology, makes diagnostic and treatment recommendations for the management of patients with hereditary, localised and advanced CRC based on the current scientific evidence on biomarker use. This consensus statement thus provides an opportunity to improve healthcare efficiency and resource use, which will benefit these patients. Based on the currently available data on this subject, this expert group recommends testing for microsatellite instability (MSI) in patients with localised CRC, as this is a strong predictive factor for deciding on adjuvant treatment. However, although the ColoPrint(®) and Oncotype Dx(®) gene expression signatures have been shown to have prognostic value, no consensus yet exists concerning their use in clinical practice. For advanced CRC, it is essential to test for KRAS mutation status before administering an anti-EGFR treatment, such as cetuximab or panitumumab. However, testing for other biomarkers, such as BRAF, EGFR, PI3K and PTEN mutations, should not be done routinely, because this does not influence treatment planning at the present time. Other important issues addressed include organisational requirements and the quality controls needed for proper testing of these biomarkers as well as the legal implications to be borne in mind when testing some biomarkers.
This consensus statement, conceived as a joint initiative of the Spanish Society of Pathology and the Spanish Society of Medical Oncology, makes diagnostic and treatment recommendations for the management of patients with hereditary, localised and advanced CRC based on the current scientific evidence on biomarker use. This consensus statement thus provides an opportunity to improve healthcare efficiency and resource use, which will benefit these patients. Based on the currently available data on this subject, this expert group recommends testing for microsatellite instability (MSI) in patients with localised CRC, as this is a strong predictive factor for deciding on adjuvant treatment. However, although the ColoPrint ® and Oncotype Dx ® gene expression signatures have been shown to have prognostic value, no consensus yet exists concerning their use in clinical practice. For advanced CRC, it is essential to test for KRAS mutation status before administering an anti-EGFR treatment, such as cetuximab or panitumumab. However, testing for other biomarkers, such as BRAF , EGFR , PI3K and PTEN mutations, should not be done routinely, because this does not influence treatment planning at the present time. Other important issues addressed include organisational requirements and the quality controls needed for proper testing of these biomarkers as well as the legal implications to be borne in mind when testing some biomarkers.
Author Musulén, Eva
Pérez-Segura, Pedro
Salazar, Ramón
García-Alfonso, Pilar
García-Foncillas, Jesús
Ramón y Cajal, Santiago
Navarro, Samuel
Payá, Artemio
García-Carbonero, Rocío
Author_xml – sequence: 1
  givenname: Pilar
  surname: García-Alfonso
  fullname: García-Alfonso, Pilar
  email: pgarcaalfonso@gmail.com
  organization: Medical Oncology Service, Universitary Hospital Gregorio Marañón, Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón
– sequence: 2
  givenname: Ramón
  surname: Salazar
  fullname: Salazar, Ramón
  organization: Medical Oncology Service, ICO Hospital Duran i Reynals
– sequence: 3
  givenname: Jesús
  surname: García-Foncillas
  fullname: García-Foncillas, Jesús
  organization: Medical Oncology Service and Genetics Clinical Unit, Clínic of Navarra University
– sequence: 4
  givenname: Eva
  surname: Musulén
  fullname: Musulén, Eva
  organization: Anatomic Pathology Service, Hospital Universitari Germans Trias i Pujol
– sequence: 5
  givenname: Rocío
  surname: García-Carbonero
  fullname: García-Carbonero, Rocío
  organization: Medical Oncology Service, Universitary Hospital Virgen del Rocío
– sequence: 6
  givenname: Artemio
  surname: Payá
  fullname: Payá, Artemio
  organization: Anatomic Pathology Service, Universitary Hospital of Alicante
– sequence: 7
  givenname: Pedro
  surname: Pérez-Segura
  fullname: Pérez-Segura, Pedro
  organization: Medical Oncology Service, Universitary Clinical Hospital San Carlos
– sequence: 8
  givenname: Santiago
  surname: Ramón y Cajal
  fullname: Ramón y Cajal, Santiago
  organization: Anatomic Pathology Service, Vall d’Hebron University Hospital
– sequence: 9
  givenname: Samuel
  surname: Navarro
  fullname: Navarro, Samuel
  organization: Anatomic Pathology Service, Medical School, University of Valencia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22855150$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1uEzEUhS1URH_gAdggL5PFwLVnPD_sqqiUSq1SEZDYWR7PncRlYqe2Z5HX4gnxNCkLJOqFfXX9nbM455ycWGeRkPcMPjKA6lNgHJoiA8YzqEWZiVfkjJVNk-UgxMlxhqL-eUrOQ3iAtC0Ze0NOOa-FYALOyO_r0XQ4GIuB9s7T1rit8r_Q04ghGrumxlLtBudRRzVQrbw2NjF0tvi2mH-miloVjbPTn7MBbRgDdT2NG6SrnbImbOjKaYNxP63vVdwkt_WezlZXl_dzqmz3P_YOO6OT79Lqv5Ll3fwted2rIeC743tBfny5-r74mt0ur28Wl7eZzosiZgp43SJv8lZ1RaEqhLqoBetEz1NYLdRMY8u1qnKoRM5LrgvIAXLN9XRDfkFmB9-dd49jSkNuTdA4DMqiG4Nk6dSiKaFJ6IcjOrZb7OTOm5TiXj7nnIDqAGjvQvDYS23iU27RKzNIBnJqVB4alalROTUqRVKyf5TP5i9p-EETEmvX6OWDG32qKLwg-gN8PrIM
CitedBy_id crossref_primary_10_1016_j_patol_2014_08_001
crossref_primary_10_1016_j_jmoldx_2014_01_003
crossref_primary_10_1093_annonc_mdz116
crossref_primary_10_3389_fphar_2024_1362217
crossref_primary_10_1515_cclm_2022_0910
crossref_primary_10_1371_journal_pone_0115672
crossref_primary_10_3343_lmo_2016_6_4_193
crossref_primary_10_1007_s00464_013_2852_4
crossref_primary_10_18632_oncotarget_3152
crossref_primary_10_3343_alm_2017_37_2_180
crossref_primary_10_1016_j_patol_2014_09_004
crossref_primary_10_1136_jclinpath_2014_202467
crossref_primary_10_2217_bmm_12_102
crossref_primary_10_1007_s12094_014_1252_0
crossref_primary_10_1016_j_pec_2023_107856
crossref_primary_10_1016_j_jval_2019_07_009
crossref_primary_10_1136_jclinpath_2013_201835
Cites_doi 10.1007/s12094-008-0147-3
10.1093/jnci/djr170
10.1056/NEJM199612053352303
10.1200/JCO.2009.27.4860
10.1200/JCO.2010.32.8732
10.1200/JCO.2004.08.186
10.1056/NEJMra012242
10.1158/0008-5472.CAN-07-5659
10.1016/j.ejca.2005.04.039
10.1038/sj.onc.1210060
10.1158/1078-0432.CCR-04-1458
10.1200/JCO.2005.00.695
10.1016/j.jmoldx.2011.03.002
10.1038/sj.bjc.6604009
10.1016/S1470-2045(10)70130-3
10.1093/jnci/djr153
10.1056/NEJMoa0805019
10.1038/sj.onc.1207262
10.1111/j.1365-2559.2009.03468.x
10.1007/s00280-010-1298-9
10.1038/bjc.2011.26
10.1200/JCO.2011.35.4498
10.1016/S1470-2045(09)70330-4
10.1080/00313020902884477
10.1093/annonc/mdq632
10.1200/JCO.2009.22.4295
10.1016/S0016-5085(99)70510-X
10.1016/S0140-6736(11)60613-2
10.1093/annonc/mdp336
10.1016/S1470-2045(05)70102-9
10.1200/JCO.2005.05.0229
10.1016/j.jss.2004.10.009
10.1001/jama.2010.1535
10.1097/PAI.0b013e3181f1da13
10.1200/JCO.2010.30.1366
10.1001/jama.296.12.1469
10.1093/jnci/djh034
10.1200/JCO.2009.27.1825
10.1038/sj.bjc.6605473
10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M
10.1200/JCO.2010.28.9538
10.1158/1078-0432.CCR-05-2734
10.1200/JCO.2008.18.6544
10.1200/JCO.2010.30.1077
10.1093/annonc/mdn541
10.1200/JCO.2009.23.3452
10.1245/s10434-009-0864-z
10.1007/s12094-010-0490-z
10.1016/j.anndiagpath.2007.12.001
10.1038/sj.bjc.6605471
10.1200/JCO.2010.33.5091
10.1200/JCO.2006.10.5437
10.1016/j.ejso.2010.12.003
10.1200/JCO.2008.20.8397
10.1002/cncr.21170
10.1200/JCO.2005.01.086
10.1200/JCO.2008.21.6796
10.1053/gast.2001.25580
10.1016/j.patol.2011.11.005
10.5858/133.10.1539
10.1093/annonc/mdr464
10.1200/jco.2011.29.4_suppl.358
ContentType Journal Article
Copyright Federación de Sociedades Españolas de Oncología (FESEO) 2012
Copyright_xml – notice: Federación de Sociedades Españolas de Oncología (FESEO) 2012
CorporateAuthor Spanish Society of Pathology (SEAP)
Spanish Society of Medical Oncology (SEOM)
CorporateAuthor_xml – name: Spanish Society of Medical Oncology (SEOM)
– name: Spanish Society of Pathology (SEAP)
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1007/s12094-012-0856-5
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1699-3055
EndPage 739
ExternalDocumentID 22855150
10_1007_s12094_012_0856_5
Genre Research Support, Non-U.S. Gov't
Journal Article
Practice Guideline
GeographicLocations Spain
GeographicLocations_xml – name: Spain
GroupedDBID -05
-0E
-5E
-5G
-BR
-EM
-S~
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
1N0
203
29B
29~
2B.
2J2
2JN
2JY
2KG
2KM
2LR
2VQ
2~H
30V
4.4
406
408
40D
40E
53G
5GY
5VR
5VS
67Z
6NX
8TC
8UJ
92I
92M
93N
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABDZT
ABECU
ABFTV
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABWNU
ABXPI
ACAOD
ACDTI
ACGFS
ACHSB
ACHVE
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACZOJ
ADHIR
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AOCGG
ARMRJ
AXYYD
B-.
BA0
BDATZ
BGNMA
BSONS
CAG
CCEZO
CHBEP
CIEJG
COF
CS3
CSCUP
DDRTE
DNIVK
DPUIP
EBLON
EBS
EIOEI
EJD
EN4
ESBYG
F5P
FA0
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
H13
HF~
HG5
HG6
HMJXF
HRMNR
HZ~
IJ-
IKXTQ
IMOTQ
IWAJR
IXD
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JUIAU
JZLTJ
KOV
KPH
LLZTM
M4Y
MA-
NPVJJ
NQJWS
NU0
O9-
O93
O9I
O9J
OAM
P2P
P9S
PF0
PT4
Q--
Q-4
QOR
QOS
R89
R9I
ROL
RPX
RSV
RT5
S16
S1Z
S27
S37
S3B
SAP
SDH
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SZ9
SZN
T13
T8U
TCJ
TSG
TSK
TSV
TT1
TUC
U1F
U1G
U2A
U5O
U9L
UG4
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WK8
YLTOR
Z45
Z7D
Z7U
Z82
Z87
ZMTXR
ZOVNA
~A9
~N8
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
AEZWR
AFDZB
AFHIU
AFOHR
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c344t-a028be293bad44a7e084851d5f2085b081ceb2ca730753262c403003c2c003c03
IEDL.DBID U2A
ISSN 1699-048X
1699-3055
IngestDate Fri Jul 11 14:30:01 EDT 2025
Thu Apr 03 06:56:57 EDT 2025
Thu Apr 24 23:06:27 EDT 2025
Tue Jul 01 03:55:41 EDT 2025
Fri Feb 21 02:34:24 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords PTEN
MSI
KRAS
BRAF
EGFR
Language English
License http://www.springer.com/tdm
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c344t-a028be293bad44a7e084851d5f2085b081ceb2ca730753262c403003c2c003c03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Instructional Material/Guideline-3
content type line 23
PMID 22855150
PQID 1111859609
PQPubID 23479
PageCount 14
ParticipantIDs proquest_miscellaneous_1111859609
pubmed_primary_22855150
crossref_citationtrail_10_1007_s12094_012_0856_5
crossref_primary_10_1007_s12094_012_0856_5
springer_journals_10_1007_s12094_012_0856_5
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20121000
2012-10-00
2012-Oct
20121001
PublicationDateYYYYMMDD 2012-10-01
PublicationDate_xml – month: 10
  year: 2012
  text: 20121000
PublicationDecade 2010
PublicationPlace Milan
PublicationPlace_xml – name: Milan
– name: Italy
PublicationTitle Clinical & translational oncology
PublicationTitleAbbrev Clin Transl Oncol
PublicationTitleAlternate Clin Transl Oncol
PublicationYear 2012
Publisher Springer Milan
Publisher_xml – name: Springer Milan
References Lynch, de la Chapelle (CR3) 2003; 348
O’Connell, Lavery, Yothers (CR25) 2010; 28
Maughan, Adams, Smith (CR37) 2011; 377
Popat, Hubner, Houlston (CR11) 2005; 23
Jhawer, Goel, Wilson (CR61) 2008; 68
Negri, Bozzetti, Lagrasta (CR48) 2010; 102
Tejpar, Saridaki, Delorenzi (CR15) 2011; 103
Croner, Peters, Brueckl (CR20) 2005; 104
Van Cutsem, Kohne, Hitre (CR32) 2009; 360
Roth, Tejpar, Delorenzi (CR31) 2010; 28
Mariani, Lae, Degeorges (CR54) 2010; 30
Roth, Tejpar, Yan (CR9) 2009; 27
CR71
Wang, Jatkoe, Zhang (CR17) 2004; 22
Douillard, Siena, Cassidy (CR40) 2010; 28
CR70
Laurent-Puig, Cayre, Manceau (CR47) 2009; 27
Sanjuan, Salas, Lloreta (CR69) 2010; 12
Bokemeyer, Bondarenko, Makhson (CR35) 2009; 27
Shibata, Reale, Lavin (CR7) 1996; 335
Khambata-Ford, Garrett, Meropol (CR44) 2007; 25
Balschun, Haag, Wenke (CR51) 2011; 13
Goldstein, Armin (CR56) 2001; 92
Folprecht, Gruenberger, Bechstein (CR36) 2010; 11
Italiano, Hostein, Soubeyran (CR53) 2010; 17
CR49
de Castro-Carpeno, Belda-Iniesta, Casado Saenz (CR59) 2008; 10
Frattini, Saletti, Romagnani (CR60) 2007; 97
Hsu, Kao, Chang (CR64) 2011; 37
Hemmings, Broomfield, Bean (CR57) 2009; 41
(CR1) 2001; 121
Kennedy, Bylesjo, Kerr (CR30) 2011; 29
Barrier, Roser, Boelle (CR22) 2007; 26
Douillard, Siena, Cassidy (CR41) 2011; 29
Ogino, Nosho, Kirkner (CR10) 2009; 27
Bertucci, Salas, Eysteries (CR16) 2004; 23
Bokemeyer, Bondarenko, Hartmann (CR34) 2011; 22
De Roock, Claes, Bernasconi (CR38) 2010; 11
Rego, Foster, Smyrk (CR58) 2010; 102
Glas, Roepman, Salazar (CR27) 2009; 27
Sinicrope, Foster, Thibodeau (CR14) 2011; 103
Perrone, Lampis, Orsenigo (CR62) 2009; 20
Sangale, Prass, Carlson (CR65) 2011; 19
Vasen, Watson, Mecklin (CR2) 1999; 116
CR55
Bouchahda, Karaboue, Saffroy (CR52) 2010; 66
Hutchins, Southward, Handley (CR13) 2011; 29
Sargent, Marsoni, Monges (CR12) 2010; 28
CR50
Popat, Houlston (CR6) 2005; 41
Lin, Friederichs, Black (CR23) 2007; 13
Gray, Quirke, Handley (CR26) 2011; 29
Spindler, Andersen, Jensen (CR45) 2010; 21
Eschrich, Yang, Bloom (CR19) 2005; 23
Washington, Berlin, Branton (CR68) 2009; 133
Salazar, Roepman, Capella (CR28) 2011; 29
Knijn, Mekenkamp, Klomp (CR42) 2011; 104
Komuro, Tada, Tamoto (CR18) 2005; 124
Mao, Yang, Hu (CR66) 2011; 23
Barrier, Boelle, Roser (CR21) 2006; 24
CR29
Alazzouzi, Alhopuro, Salovaara (CR8) 2005; 11
Van Cutsem, Kohne, Lang (CR33) 2011; 29
De Roock, Jonker, Di Nicolantonio (CR39) 2010; 304
Balmana, Stockwell, Steyerberg (CR5) 2006; 296
Vendrell, Ribas, Valls (CR24) 2007; 30
Moroni, Veronese, Benvenuti (CR46) 2005; 6
Umar, Boland, Terdiman (CR4) 2004; 96
Jang, Song, Jang (CR63) 2010; 56
Shtilbans, Wu, Burstein (CR67) 2008; 12
Richman, Seymour, Chambers (CR43) 2009; 27
G Hutchins (856_CR13) 2011; 29
TS Maughan (856_CR37) 2011; 377
A Italiano (856_CR53) 2010; 17
D Shibata (856_CR7) 1996; 335
C Hemmings (856_CR57) 2009; 41
E Cutsem Van (856_CR32) 2009; 360
HF Vasen (856_CR2) 1999; 116
YH Lin (856_CR23) 2007; 13
RG Gray (856_CR26) 2011; 29
S Khambata-Ford (856_CR44) 2007; 25
HT Lynch (856_CR3) 2003; 348
AD Roth (856_CR31) 2010; 28
J Douillard (856_CR41) 2011; 29
856_CR55
856_CR50
S Eschrich (856_CR19) 2005; 23
W Roock De (856_CR38) 2010; 11
V Shtilbans (856_CR67) 2008; 12
NS Goldstein (856_CR56) 2001; 92
F Perrone (856_CR62) 2009; 20
N Knijn (856_CR42) 2011; 104
Z Sangale (856_CR65) 2011; 19
E Vendrell (856_CR24) 2007; 30
A Barrier (856_CR22) 2007; 26
E Cutsem Van (856_CR33) 2011; 29
J Castro-Carpeno de (856_CR59) 2008; 10
J Balmana (856_CR5) 2006; 296
RS Croner (856_CR20) 2005; 104
RD Kennedy (856_CR30) 2011; 29
S Ogino (856_CR10) 2009; 27
S Tejpar (856_CR15) 2011; 103
856_CR49
RL Rego (856_CR58) 2010; 102
C Bokemeyer (856_CR34) 2011; 22
SD Richman (856_CR43) 2009; 27
P Mariani (856_CR54) 2010; 30
CP Hsu (856_CR64) 2011; 37
G Folprecht (856_CR36) 2010; 11
S Popat (856_CR11) 2005; 23
KS Jang (856_CR63) 2010; 56
856_CR70
856_CR71
R Salazar (856_CR28) 2011; 29
FA Sinicrope (856_CR14) 2011; 103
MK Washington (856_CR68) 2009; 133
856_CR1
MJ O’Connell (856_CR25) 2010; 28
AD Roth (856_CR9) 2009; 27
A Barrier (856_CR21) 2006; 24
K Balschun (856_CR51) 2011; 13
F Bertucci (856_CR16) 2004; 23
M Jhawer (856_CR61) 2008; 68
H Alazzouzi (856_CR8) 2005; 11
P Laurent-Puig (856_CR47) 2009; 27
FV Negri (856_CR48) 2010; 102
DJ Sargent (856_CR12) 2010; 28
A Umar (856_CR4) 2004; 96
X Sanjuan (856_CR69) 2010; 12
Y Wang (856_CR17) 2004; 22
AM Glas (856_CR27) 2009; 27
C Bokemeyer (856_CR35) 2009; 27
KL Spindler (856_CR45) 2010; 21
856_CR29
M Frattini (856_CR60) 2007; 97
JY Douillard (856_CR40) 2010; 28
M Bouchahda (856_CR52) 2010; 66
M Moroni (856_CR46) 2005; 6
S Popat (856_CR6) 2005; 41
K Komuro (856_CR18) 2005; 124
W Roock De (856_CR39) 2010; 304
856_CR66
19114683 - J Clin Oncol. 2009 Feb 10;27(5):663-71
19237633 - J Clin Oncol. 2009 Mar 20;27(9):1477-84
14970275 - J Natl Cancer Inst. 2004 Feb 18;96(4):261-8
17003395 - JAMA. 2006 Sep 27;296(12 ):1469-78
12621137 - N Engl J Med. 2003 Mar 6;348(10):919-32
17255271 - Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):498-507
19850635 - Ann Oncol. 2010 Mar;21(3):535-9
24718886 - Ann Oncol. 2014 Jul;25(7):1346-55
21098318 - J Clin Oncol. 2011 Jan 1;29(1):17-24
19884556 - J Clin Oncol. 2009 Dec 10;27(35):5924-30
22039088 - Ann Oncol. 2012 Jun;23 (6):1518-25
20102402 - Histopathology. 2010 Jan;56(2):229-39
17940504 - Br J Cancer. 2007 Oct 22;97(8):1139-45
21597022 - J Natl Cancer Inst. 2011 Jun 8;103(11):863-75
17664471 - J Clin Oncol. 2007 Aug 1;25(22):3230-7
15051756 - J Clin Oncol. 2004 May 1;22(9):1564-71
18208787 - Clin Transl Oncol. 2008 Jan;10 (1):6-13
22067406 - J Clin Oncol. 2011 Dec 10;29(35):4620-6
15863375 - Lancet Oncol. 2005 May;6(5):279-86
15659508 - J Clin Oncol. 2005 Jan 20;23(3):609-18
20008640 - J Clin Oncol. 2010 Jan 20;28(3):466-74
21597023 - J Natl Cancer Inst. 2011 Jun 8;103(11):841-4
15814640 - Clin Cancer Res. 2005 Apr 1;11(7):2606-11
19884549 - J Clin Oncol. 2009 Dec 10;27(35):5931-7
15820251 - J Surg Res. 2005 Apr;124(2):216-24
18325479 - Ann Diagn Pathol. 2008 Apr;12(2):153-60
18339877 - Cancer Res. 2008 Mar 15;68(6):1953-61
16125380 - Eur J Cancer. 2005 Sep;41(14):2060-70
18669866 - Ann Oncol. 2009 Jan;20(1):84-90
20978259 - JAMA. 2010 Oct 27;304(16):1812-20
21036746 - Anticancer Res. 2010 Oct;30(10):4229-35
19339720 - N Engl J Med. 2009 Apr 2;360(14):1408-17
21194879 - Eur J Surg Oncol. 2011 Feb;37(2):140-7
20921465 - J Clin Oncol. 2010 Nov 1;28(31):4697-705
19792043 - Arch Pathol Lab Med. 2009 Oct;133(10):1539-51
11571750 - Cancer. 2001 Sep 1;92(5):1331-46
20231125 - Clin Transl Oncol. 2010 Mar;12(3):211-3
19942479 - Lancet Oncol. 2010 Jan;11(1):38-47
16966692 - J Clin Oncol. 2006 Oct 10;24(29):4685-91
20049644 - Ann Surg Oncol. 2010 May;17 (5):1429-34
21228335 - Ann Oncol. 2011 Jul;22(7):1535-46
20619739 - Lancet Oncol. 2010 Aug;11(8):753-62
19997103 - Br J Cancer. 2010 Jan 5;102(1):165-72
20498393 - J Clin Oncol. 2010 Jul 10;28(20):3219-26
22067390 - J Clin Oncol. 2011 Dec 10;29(35):4611-9
17390011 - Int J Oncol. 2007 May;30(5):1099-107
10348829 - Gastroenterology. 1999 Jun;116(6):1453-6
11438508 - Gastroenterology. 2001 Jul;121(1):195-7
20679606 - J Clin Oncol. 2010 Sep 1;28(25):3937-44
20930614 - Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):173-83
21704278 - J Mol Diagn. 2011 Jul;13(4):436-45
20361188 - Cancer Chemother Pharmacol. 2010 Aug;66(3):605-9
14973550 - Oncogene. 2004 Feb 19;23(7):1377-91
15908663 - J Clin Oncol. 2005 May 20;23(15):3526-35
15952189 - Cancer. 2005 Jul 15;104(2):395-404
21383284 - J Clin Oncol. 2011 Apr 1;29(10 ):1261-70
21641636 - Lancet. 2011 Jun 18;377(9783):2103-14
19953097 - Br J Cancer. 2010 Jan 5;102(1):162-4
21502544 - J Clin Oncol. 2011 May 20;29(15):2011-9
21364579 - Br J Cancer. 2011 Mar 15;104(6):1020-6
8929264 - N Engl J Med. 1996 Dec 5;335(23):1727-32
17043639 - Oncogene. 2007 Apr 19;26(18):2642-8
19404848 - Pathology. 2009;41(4):356-60
References_xml – ident: CR70
– volume: 10
  start-page: 6
  year: 2008
  end-page: 13
  ident: CR59
  article-title: EGFR and colon cancer: a clinical view
  publication-title: Clin Transl Oncol
  doi: 10.1007/s12094-008-0147-3
– volume: 103
  start-page: 841
  year: 2011
  end-page: 844
  ident: CR15
  article-title: Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djr170
– ident: CR49
– volume: 335
  start-page: 1727
  year: 1996
  end-page: 1732
  ident: CR7
  article-title: The DCC protein and prognosis in colorectal cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199612053352303
– volume: 28
  start-page: 4697
  year: 2010
  end-page: 4705
  ident: CR40
  article-title: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.27.4860
– volume: 30
  start-page: 4229
  year: 2010
  end-page: 4235
  ident: CR54
  article-title: Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis
  publication-title: Anticancer Res
– volume: 29
  start-page: 4611
  year: 2011
  end-page: 4619
  ident: CR26
  article-title: Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.32.8732
– volume: 133
  start-page: 1539
  year: 2009
  end-page: 1551
  ident: CR68
  article-title: Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum
  publication-title: Arch Pathol Lab Med
– volume: 22
  start-page: 1564
  year: 2004
  end-page: 1571
  ident: CR17
  article-title: Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.08.186
– volume: 348
  start-page: 919
  year: 2003
  end-page: 932
  ident: CR3
  article-title: Hereditary colorectal cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra012242
– volume: 68
  start-page: 1953
  year: 2008
  end-page: 1961
  ident: CR61
  article-title: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-5659
– volume: 41
  start-page: 2060
  year: 2005
  end-page: 2070
  ident: CR6
  article-title: A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2005.04.039
– ident: CR29
– volume: 26
  start-page: 2642
  year: 2007
  end-page: 2648
  ident: CR22
  article-title: Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210060
– volume: 11
  start-page: 2606
  year: 2005
  end-page: 2611
  ident: CR8
  article-title: SMAD4 as a prognostic marker in colorectal cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-1458
– volume: 23
  start-page: 3526
  year: 2005
  end-page: 3535
  ident: CR19
  article-title: Molecular staging for survival prediction of colorectal cancer patients
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.00.695
– volume: 13
  start-page: 436
  year: 2011
  end-page: 445
  ident: CR51
  article-title: KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications
  publication-title: J Mol Diagn
  doi: 10.1016/j.jmoldx.2011.03.002
– volume: 23
  start-page: 1518
  issue: 6
  year: 2011
  end-page: 1525
  ident: CR66
  article-title: PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
  publication-title: Ann Oncol
– volume: 97
  start-page: 1139
  year: 2007
  end-page: 1145
  ident: CR60
  article-title: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6604009
– volume: 11
  start-page: 753
  year: 2010
  end-page: 762
  ident: CR38
  article-title: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(10)70130-3
– ident: CR71
– volume: 103
  start-page: 863
  year: 2011
  end-page: 875
  ident: CR14
  article-title: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djr153
– volume: 360
  start-page: 1408
  year: 2009
  end-page: 1417
  ident: CR32
  article-title: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0805019
– volume: 23
  start-page: 1377
  year: 2004
  end-page: 1391
  ident: CR16
  article-title: Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1207262
– ident: CR50
– volume: 56
  start-page: 229
  year: 2010
  end-page: 239
  ident: CR63
  article-title: Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.2009.03468.x
– volume: 66
  start-page: 605
  year: 2010
  end-page: 609
  ident: CR52
  article-title: Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-010-1298-9
– volume: 30
  start-page: 1099
  year: 2007
  end-page: 1107
  ident: CR24
  article-title: Genomic and transcriptomic prognostic factors in R0 Dukes B and C colorectal cancer patients
  publication-title: Int J Oncol
– volume: 104
  start-page: 1020
  year: 2011
  end-page: 1026
  ident: CR42
  article-title: KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2011.26
– volume: 29
  start-page: 4620
  year: 2011
  end-page: 4626
  ident: CR30
  article-title: Development and independent validation of a prognostic assay for stage ii colon cancer using formalin-fixed paraffin-embedded tissue
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.35.4498
– volume: 11
  start-page: 38
  year: 2010
  end-page: 47
  ident: CR36
  article-title: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(09)70330-4
– volume: 41
  start-page: 356
  year: 2009
  end-page: 360
  ident: CR57
  article-title: Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH
  publication-title: Pathology
  doi: 10.1080/00313020902884477
– volume: 22
  start-page: 1535
  year: 2011
  end-page: 1546
  ident: CR34
  article-title: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdq632
– volume: 27
  start-page: 5931
  year: 2009
  end-page: 5937
  ident: CR43
  article-title: KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.22.4295
– volume: 116
  start-page: 1453
  year: 1999
  end-page: 1456
  ident: CR2
  article-title: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(99)70510-X
– volume: 377
  start-page: 2103
  year: 2011
  end-page: 2114
  ident: CR37
  article-title: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)60613-2
– volume: 29
  start-page: 3510
  year: 2011
  ident: CR41
  article-title: Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC)
  publication-title: ASCO Meet Abstr
– volume: 21
  start-page: 535
  year: 2010
  end-page: 539
  ident: CR45
  article-title: EGF61A > G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdp336
– volume: 6
  start-page: 279
  year: 2005
  end-page: 286
  ident: CR46
  article-title: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(05)70102-9
– volume: 24
  start-page: 4685
  year: 2006
  end-page: 4691
  ident: CR21
  article-title: Stage II colon cancer prognosis prediction by tumor gene expression profiling
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.05.0229
– volume: 27
  start-page: 4002
  year: 2009
  ident: CR9
  article-title: Stage-specific prognostic value of molecular markers in colon cancer: results of the translational study on the PETACC 3–EORTC 40993–SAKK 60-00 trial
  publication-title: ASCO Meeting Abstracts
– volume: 124
  start-page: 216
  year: 2005
  end-page: 224
  ident: CR18
  article-title: Right- and left-sided colorectal cancers display distinct expression profiles and the anatomical stratification allows a high accuracy prediction of lymph node metastasis
  publication-title: J Surg Res
  doi: 10.1016/j.jss.2004.10.009
– volume: 304
  start-page: 1812
  year: 2010
  end-page: 1820
  ident: CR39
  article-title: Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
  publication-title: JAMA
  doi: 10.1001/jama.2010.1535
– volume: 19
  start-page: 173
  year: 2011
  end-page: 183
  ident: CR65
  article-title: A robust immunohistochemical assay for detecting PTEN expression in human tumors
  publication-title: Appl Immunohistochem Mol Morphol
  doi: 10.1097/PAI.0b013e3181f1da13
– volume: 121
  start-page: 195
  year: 2001
  end-page: 197
  ident: CR1
  article-title: American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing
  publication-title: Gastroenterology
– volume: 29
  start-page: 1261
  year: 2011
  end-page: 1270
  ident: CR13
  article-title: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.30.1366
– volume: 296
  start-page: 1469
  year: 2006
  end-page: 1478
  ident: CR5
  article-title: Prediction of MLH1 and MSH2 mutations in Lynch syndrome
  publication-title: JAMA
  doi: 10.1001/jama.296.12.1469
– volume: 96
  start-page: 261
  year: 2004
  end-page: 268
  ident: CR4
  article-title: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djh034
– volume: 28
  start-page: 3219
  year: 2010
  end-page: 3226
  ident: CR12
  article-title: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.27.1825
– volume: 102
  start-page: 165
  year: 2010
  end-page: 172
  ident: CR58
  article-title: Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6605473
– volume: 92
  start-page: 1331
  year: 2001
  end-page: 1346
  ident: CR56
  article-title: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system
  publication-title: Cancer
  doi: 10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M
– volume: 28
  start-page: 3937
  year: 2010
  end-page: 3944
  ident: CR25
  article-title: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.28.9538
– volume: 13
  start-page: 498
  year: 2007
  end-page: 507
  ident: CR23
  article-title: Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-05-2734
– volume: 27
  start-page: 1477
  year: 2009
  end-page: 1484
  ident: CR10
  article-title: PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.18.6544
– volume: 29
  start-page: 17
  year: 2011
  end-page: 24
  ident: CR28
  article-title: Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.30.1077
– volume: 20
  start-page: 84
  year: 2009
  end-page: 90
  ident: CR62
  article-title: PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdn541
– volume: 28
  start-page: 466
  year: 2010
  end-page: 474
  ident: CR31
  article-title: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.23.3452
– volume: 17
  start-page: 1429
  year: 2010
  end-page: 1434
  ident: CR53
  article-title: KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-009-0864-z
– volume: 12
  start-page: 211
  year: 2010
  end-page: 213
  ident: CR69
  article-title: Colorectal Cancer OncoGuia: surgical pathology report guidelines
  publication-title: Clin Transl Oncol
  doi: 10.1007/s12094-010-0490-z
– volume: 12
  start-page: 153
  year: 2008
  end-page: 160
  ident: CR67
  article-title: Current overview of the role of Akt in cancer studies via applied immunohistochemistry
  publication-title: Ann Diagn Pathol
  doi: 10.1016/j.anndiagpath.2007.12.001
– volume: 102
  start-page: 162
  year: 2010
  end-page: 164
  ident: CR48
  article-title: PTEN status in advanced colorectal cancer treated with cetuximab
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6605471
– volume: 29
  start-page: 2011
  year: 2011
  end-page: 2019
  ident: CR33
  article-title: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.33.5091
– volume: 25
  start-page: 3230
  year: 2007
  end-page: 3237
  ident: CR44
  article-title: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.10.5437
– volume: 37
  start-page: 140
  year: 2011
  end-page: 147
  ident: CR64
  article-title: Clinical significance of tumor suppressor PTEN in colorectal carcinoma
  publication-title: Eur J Surg Oncol
  doi: 10.1016/j.ejso.2010.12.003
– volume: 27
  start-page: 4036
  year: 2009
  ident: CR27
  article-title: Development and validation of a robust prognostic and predictive signature for colorectal cancer (CRC) patients
  publication-title: ASCO Meet Abstr
– ident: CR55
– volume: 27
  start-page: 663
  year: 2009
  end-page: 671
  ident: CR35
  article-title: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.20.8397
– volume: 104
  start-page: 395
  year: 2005
  end-page: 404
  ident: CR20
  article-title: Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma
  publication-title: Cancer
  doi: 10.1002/cncr.21170
– volume: 23
  start-page: 609
  year: 2005
  end-page: 618
  ident: CR11
  article-title: Systematic review of microsatellite instability and colorectal cancer prognosis
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.01.086
– volume: 27
  start-page: 5924
  year: 2009
  end-page: 5930
  ident: CR47
  article-title: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.21.6796
– volume: 10
  start-page: 6
  year: 2008
  ident: 856_CR59
  publication-title: Clin Transl Oncol
  doi: 10.1007/s12094-008-0147-3
– volume: 104
  start-page: 395
  year: 2005
  ident: 856_CR20
  publication-title: Cancer
  doi: 10.1002/cncr.21170
– volume: 26
  start-page: 2642
  year: 2007
  ident: 856_CR22
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210060
– ident: 856_CR1
  doi: 10.1053/gast.2001.25580
– volume: 27
  start-page: 4002
  year: 2009
  ident: 856_CR9
  publication-title: ASCO Meeting Abstracts
– ident: 856_CR50
– ident: 856_CR55
  doi: 10.1016/j.patol.2011.11.005
– volume: 360
  start-page: 1408
  year: 2009
  ident: 856_CR32
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0805019
– volume: 27
  start-page: 4036
  year: 2009
  ident: 856_CR27
  publication-title: ASCO Meet Abstr
– volume: 335
  start-page: 1727
  year: 1996
  ident: 856_CR7
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199612053352303
– volume: 23
  start-page: 3526
  year: 2005
  ident: 856_CR19
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.00.695
– volume: 66
  start-page: 605
  year: 2010
  ident: 856_CR52
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-010-1298-9
– volume: 22
  start-page: 1535
  year: 2011
  ident: 856_CR34
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdq632
– volume: 22
  start-page: 1564
  year: 2004
  ident: 856_CR17
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.08.186
– volume: 41
  start-page: 356
  year: 2009
  ident: 856_CR57
  publication-title: Pathology
  doi: 10.1080/00313020902884477
– volume: 96
  start-page: 261
  year: 2004
  ident: 856_CR4
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djh034
– volume: 56
  start-page: 229
  year: 2010
  ident: 856_CR63
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.2009.03468.x
– volume: 6
  start-page: 279
  year: 2005
  ident: 856_CR46
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(05)70102-9
– volume: 20
  start-page: 84
  year: 2009
  ident: 856_CR62
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdn541
– volume: 92
  start-page: 1331
  year: 2001
  ident: 856_CR56
  publication-title: Cancer
  doi: 10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M
– volume: 103
  start-page: 841
  year: 2011
  ident: 856_CR15
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djr170
– volume: 28
  start-page: 4697
  year: 2010
  ident: 856_CR40
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.27.4860
– volume: 11
  start-page: 2606
  year: 2005
  ident: 856_CR8
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-1458
– volume: 28
  start-page: 3937
  year: 2010
  ident: 856_CR25
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.28.9538
– volume: 19
  start-page: 173
  year: 2011
  ident: 856_CR65
  publication-title: Appl Immunohistochem Mol Morphol
  doi: 10.1097/PAI.0b013e3181f1da13
– volume: 29
  start-page: 4620
  year: 2011
  ident: 856_CR30
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.35.4498
– volume: 27
  start-page: 663
  year: 2009
  ident: 856_CR35
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.20.8397
– volume: 17
  start-page: 1429
  year: 2010
  ident: 856_CR53
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-009-0864-z
– volume: 25
  start-page: 3230
  year: 2007
  ident: 856_CR44
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.10.5437
– volume: 296
  start-page: 1469
  year: 2006
  ident: 856_CR5
  publication-title: JAMA
  doi: 10.1001/jama.296.12.1469
– volume: 27
  start-page: 5931
  year: 2009
  ident: 856_CR43
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.22.4295
– volume: 27
  start-page: 5924
  year: 2009
  ident: 856_CR47
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.21.6796
– volume: 28
  start-page: 3219
  year: 2010
  ident: 856_CR12
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.27.1825
– volume: 29
  start-page: 4611
  year: 2011
  ident: 856_CR26
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.32.8732
– ident: 856_CR49
– volume: 23
  start-page: 609
  year: 2005
  ident: 856_CR11
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.01.086
– volume: 124
  start-page: 216
  year: 2005
  ident: 856_CR18
  publication-title: J Surg Res
  doi: 10.1016/j.jss.2004.10.009
– volume: 24
  start-page: 4685
  year: 2006
  ident: 856_CR21
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.05.0229
– volume: 30
  start-page: 1099
  year: 2007
  ident: 856_CR24
  publication-title: Int J Oncol
– volume: 21
  start-page: 535
  year: 2010
  ident: 856_CR45
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdp336
– volume: 29
  start-page: 17
  year: 2011
  ident: 856_CR28
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.30.1077
– volume: 133
  start-page: 1539
  year: 2009
  ident: 856_CR68
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/133.10.1539
– volume: 29
  start-page: 1261
  year: 2011
  ident: 856_CR13
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.30.1366
– volume: 377
  start-page: 2103
  year: 2011
  ident: 856_CR37
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)60613-2
– volume: 41
  start-page: 2060
  year: 2005
  ident: 856_CR6
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2005.04.039
– volume: 13
  start-page: 498
  year: 2007
  ident: 856_CR23
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-05-2734
– volume: 29
  start-page: 3510
  year: 2011
  ident: 856_CR41
  publication-title: ASCO Meet Abstr
– volume: 23
  start-page: 1377
  year: 2004
  ident: 856_CR16
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1207262
– ident: 856_CR71
– volume: 103
  start-page: 863
  year: 2011
  ident: 856_CR14
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djr153
– volume: 11
  start-page: 38
  year: 2010
  ident: 856_CR36
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(09)70330-4
– volume: 304
  start-page: 1812
  year: 2010
  ident: 856_CR39
  publication-title: JAMA
  doi: 10.1001/jama.2010.1535
– volume: 37
  start-page: 140
  year: 2011
  ident: 856_CR64
  publication-title: Eur J Surg Oncol
  doi: 10.1016/j.ejso.2010.12.003
– volume: 348
  start-page: 919
  year: 2003
  ident: 856_CR3
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra012242
– volume: 12
  start-page: 211
  year: 2010
  ident: 856_CR69
  publication-title: Clin Transl Oncol
  doi: 10.1007/s12094-010-0490-z
– ident: 856_CR66
  doi: 10.1093/annonc/mdr464
– volume: 12
  start-page: 153
  year: 2008
  ident: 856_CR67
  publication-title: Ann Diagn Pathol
  doi: 10.1016/j.anndiagpath.2007.12.001
– volume: 102
  start-page: 165
  year: 2010
  ident: 856_CR58
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6605473
– volume: 29
  start-page: 2011
  year: 2011
  ident: 856_CR33
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.33.5091
– volume: 30
  start-page: 4229
  year: 2010
  ident: 856_CR54
  publication-title: Anticancer Res
– ident: 856_CR70
– volume: 11
  start-page: 753
  year: 2010
  ident: 856_CR38
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(10)70130-3
– volume: 102
  start-page: 162
  year: 2010
  ident: 856_CR48
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6605471
– volume: 116
  start-page: 1453
  year: 1999
  ident: 856_CR2
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(99)70510-X
– volume: 13
  start-page: 436
  year: 2011
  ident: 856_CR51
  publication-title: J Mol Diagn
  doi: 10.1016/j.jmoldx.2011.03.002
– ident: 856_CR29
  doi: 10.1200/jco.2011.29.4_suppl.358
– volume: 104
  start-page: 1020
  year: 2011
  ident: 856_CR42
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2011.26
– volume: 27
  start-page: 1477
  year: 2009
  ident: 856_CR10
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.18.6544
– volume: 68
  start-page: 1953
  year: 2008
  ident: 856_CR61
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-5659
– volume: 28
  start-page: 466
  year: 2010
  ident: 856_CR31
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.23.3452
– volume: 97
  start-page: 1139
  year: 2007
  ident: 856_CR60
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6604009
– reference: 14973550 - Oncogene. 2004 Feb 19;23(7):1377-91
– reference: 15814640 - Clin Cancer Res. 2005 Apr 1;11(7):2606-11
– reference: 21364579 - Br J Cancer. 2011 Mar 15;104(6):1020-6
– reference: 18325479 - Ann Diagn Pathol. 2008 Apr;12(2):153-60
– reference: 20679606 - J Clin Oncol. 2010 Sep 1;28(25):3937-44
– reference: 20619739 - Lancet Oncol. 2010 Aug;11(8):753-62
– reference: 20008640 - J Clin Oncol. 2010 Jan 20;28(3):466-74
– reference: 16966692 - J Clin Oncol. 2006 Oct 10;24(29):4685-91
– reference: 22067390 - J Clin Oncol. 2011 Dec 10;29(35):4611-9
– reference: 21704278 - J Mol Diagn. 2011 Jul;13(4):436-45
– reference: 21597022 - J Natl Cancer Inst. 2011 Jun 8;103(11):863-75
– reference: 21228335 - Ann Oncol. 2011 Jul;22(7):1535-46
– reference: 19792043 - Arch Pathol Lab Med. 2009 Oct;133(10):1539-51
– reference: 18339877 - Cancer Res. 2008 Mar 15;68(6):1953-61
– reference: 21194879 - Eur J Surg Oncol. 2011 Feb;37(2):140-7
– reference: 8929264 - N Engl J Med. 1996 Dec 5;335(23):1727-32
– reference: 12621137 - N Engl J Med. 2003 Mar 6;348(10):919-32
– reference: 17003395 - JAMA. 2006 Sep 27;296(12 ):1469-78
– reference: 19942479 - Lancet Oncol. 2010 Jan;11(1):38-47
– reference: 19884556 - J Clin Oncol. 2009 Dec 10;27(35):5924-30
– reference: 19953097 - Br J Cancer. 2010 Jan 5;102(1):162-4
– reference: 15659508 - J Clin Oncol. 2005 Jan 20;23(3):609-18
– reference: 19339720 - N Engl J Med. 2009 Apr 2;360(14):1408-17
– reference: 15820251 - J Surg Res. 2005 Apr;124(2):216-24
– reference: 11571750 - Cancer. 2001 Sep 1;92(5):1331-46
– reference: 20102402 - Histopathology. 2010 Jan;56(2):229-39
– reference: 19850635 - Ann Oncol. 2010 Mar;21(3):535-9
– reference: 17940504 - Br J Cancer. 2007 Oct 22;97(8):1139-45
– reference: 21597023 - J Natl Cancer Inst. 2011 Jun 8;103(11):841-4
– reference: 20361188 - Cancer Chemother Pharmacol. 2010 Aug;66(3):605-9
– reference: 21383284 - J Clin Oncol. 2011 Apr 1;29(10 ):1261-70
– reference: 16125380 - Eur J Cancer. 2005 Sep;41(14):2060-70
– reference: 22067406 - J Clin Oncol. 2011 Dec 10;29(35):4620-6
– reference: 20930614 - Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):173-83
– reference: 22039088 - Ann Oncol. 2012 Jun;23 (6):1518-25
– reference: 17664471 - J Clin Oncol. 2007 Aug 1;25(22):3230-7
– reference: 15863375 - Lancet Oncol. 2005 May;6(5):279-86
– reference: 20921465 - J Clin Oncol. 2010 Nov 1;28(31):4697-705
– reference: 19237633 - J Clin Oncol. 2009 Mar 20;27(9):1477-84
– reference: 21502544 - J Clin Oncol. 2011 May 20;29(15):2011-9
– reference: 21098318 - J Clin Oncol. 2011 Jan 1;29(1):17-24
– reference: 20498393 - J Clin Oncol. 2010 Jul 10;28(20):3219-26
– reference: 15952189 - Cancer. 2005 Jul 15;104(2):395-404
– reference: 20978259 - JAMA. 2010 Oct 27;304(16):1812-20
– reference: 19884549 - J Clin Oncol. 2009 Dec 10;27(35):5931-7
– reference: 18208787 - Clin Transl Oncol. 2008 Jan;10 (1):6-13
– reference: 10348829 - Gastroenterology. 1999 Jun;116(6):1453-6
– reference: 20049644 - Ann Surg Oncol. 2010 May;17 (5):1429-34
– reference: 15051756 - J Clin Oncol. 2004 May 1;22(9):1564-71
– reference: 11438508 - Gastroenterology. 2001 Jul;121(1):195-7
– reference: 17390011 - Int J Oncol. 2007 May;30(5):1099-107
– reference: 20231125 - Clin Transl Oncol. 2010 Mar;12(3):211-3
– reference: 19404848 - Pathology. 2009;41(4):356-60
– reference: 17255271 - Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):498-507
– reference: 18669866 - Ann Oncol. 2009 Jan;20(1):84-90
– reference: 19997103 - Br J Cancer. 2010 Jan 5;102(1):165-72
– reference: 17043639 - Oncogene. 2007 Apr 19;26(18):2642-8
– reference: 14970275 - J Natl Cancer Inst. 2004 Feb 18;96(4):261-8
– reference: 24718886 - Ann Oncol. 2014 Jul;25(7):1346-55
– reference: 15908663 - J Clin Oncol. 2005 May 20;23(15):3526-35
– reference: 19114683 - J Clin Oncol. 2009 Feb 10;27(5):663-71
– reference: 21641636 - Lancet. 2011 Jun 18;377(9783):2103-14
– reference: 21036746 - Anticancer Res. 2010 Oct;30(10):4229-35
SSID ssj0055611
Score 2.039806
Snippet This consensus statement, conceived as a joint initiative of the Spanish Society of Pathology and the Spanish Society of Medical Oncology, makes diagnostic and...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 726
SubjectTerms Algorithms
Biomarkers, Tumor - analysis
Biomarkers, Tumor - genetics
Carcinoma - diagnosis
Carcinoma - genetics
Colorectal Neoplasms - diagnosis
Colorectal Neoplasms - genetics
Consensus
Diagnostic Techniques and Procedures
Humans
Medical Oncology - legislation & jurisprudence
Medical Oncology - organization & administration
Medicine
Medicine & Public Health
Microsatellite Instability
Oncology
Pathology, Clinical - legislation & jurisprudence
Pathology, Clinical - organization & administration
Practice Guidelines as Topic
Prognosis
Societies, Medical - legislation & jurisprudence
Societies, Medical - organization & administration
Spain
Special Article
Title Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
URI https://link.springer.com/article/10.1007/s12094-012-0856-5
https://www.ncbi.nlm.nih.gov/pubmed/22855150
https://www.proquest.com/docview/1111859609
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8NAEB58gHgR39YXI3iwSiDd7KbRWy2tolRFLdRT2GxSLchWTHrwb_kLnUmTivgALwmE2c1hdme_2Zn5BmC_pgNyNPy-U9dx3ZGEsJ1A0caL-q7x615NK4_rnTtX_nlXXvRUr6jjTsts9zIkmVvqz2I34TKNLacSBMp31DTMKnbdaRF3RaM0v9zuMfeyfC6vl0GvDGX-NMXXw-gbwvwWHc0PnfYiLBRoERtj9S7BVGKXYa5TxMNX4P1sxDRVnLqOhD6Ri-k53-YVM2bPsI84sMi81GzXaCLDnYMsyeBB87ZZPUGN5W0gifE1czpKcdhHgoV4R4ZikD5hkdjJn290llvLNzy4azVuqqht_JtsEQLCa2smQ6471VXotlv3zXOn6MLgGE_KzNGEQKKEUEGkYyl1PWEGflWLVZ_be0YEKQx550aTqSDXR_jCSDIcrmeE4afrrcGMHdpkAzCSiQm4GNfzmdXHRMcEz5TQsfBiLwlqFXBLdYSmoCjnThnP4Se5MmswJA2GrMFQVeBwMuRlzM_xl_BeqeOQdhGHRrRNhqM094MCxex7FVgfK38ynRABwUrlVuCoXA1hsdHT3_-1-S_pLZgXvCzzLMFtmMleR8kOoZ0s2oXZRvv09IrfZw-Xrd18tX8A9lX12Q
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT-MwEB4BKwEXxPIssDArcaCgSKljp4ZbVQGFpYCASr1FjpPuIiEXkfTA3-IXMpMmRSseEpccrLFzGHv8jWfmG4DdhtHkaIQDr2mSpicJYXta0cGLB74Nm0HDqIDrnbuXYacnz_uqX9ZxZ1W2exWSLCz1W7Gb8JnGllMJtAo9NQ0_CAtozuPqiVZlfrndY-FlhVxeL3W_CmV-tMT_l9E7hPkuOlpcOieLsFCiRWyN1fsTplK3BLPdMh6-DC-nI6ap4tR1JPSJXEzP-TZPmDN7hvuL9w6Zl5rtGi1kuXOQIxnca9-060dosHoNJDF-Zs5GGQ4HSLAQb8lQ3Gf_sEzs5OFrkxfW8hn3bo9b13U0LvlMtgwB4ZWzkylX3foK9E6O79odr-zC4NlAytwzhEDilFBBbBIpTTNlBn7VSNSA23vGBCkseefWkKkg10eEwkoyHH5gheWvH6zCjBu6dB0wlqnVXIwbhMzqY-NDgmdKmEQESZDqRg38Sh2RLSnKuVPGQ_RGrswajEiDEWswUjXYn0x5HPNzfCX8u9JxRKeIQyPGpcNRVvhBWjH7Xg3WxsqfLCeEJlip_BocVLshKg969vm_Nr4lvQNznbvuRXRxdvlnE-YFb9EiY3ALZvKnUfqLkE8ebxc7_RVNq_W8
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9tAEB5RkFAvqEBb0vIYJA6klYW93nUMtyiQUmggKo2Um7Ve24CENlHsHPq3-IXMOHYQ4iFx8cGaXR9mdvYbz8w3AHueDinQCDKnpZOWIwlhO6GigxdnrglavqeVz_3OvYvgdCDPhmpYzTnN62r3OiU562lgliZbHIyT7OCx8U24TGnLZQWhChz1AZbIG3ts1gPRrl0xj34sI66AW-1lOKzTmi9t8fRieoY2n2VKywuo-wlWKuSI7ZmqV2EhtWuw3Kty4-tw_2vKlFVcxo6ERJEb67n2ZoIFM2nYa7y1yBzV7ONoI8NThCzJ4H7nb6d5hBrrP4Mkxr-c82mOowwJIuIVOY3b_AarIk9-3ddF6Tn_4_7VSbvfRG2T12SrdBBeWjNfctlrfoZB9-Rf59SpJjI4xpeycDShkTglhBDrRErdSpmNX3mJynjUZ0zwwlCkbjS5DQqDRCCMJCfi-kYYfrr-F1i0I5tuAMYyNSE35voBM_yY-JCgmhI6EX7ip6HXALdWR2QqunKemnEXPRItswYj0mDEGoxUA37Ml4xnXB1vCe_WOo7oRHGaRNt0NM3LmChUzMTXgK8z5c-3EyIkiKncBvysrSGqDn3--re-vUt6B5b7x93oz--L8-_wUbCFlsWDm7BYTKbpFoGgIt4uDf0Bi9D5-A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Guidelines+for+biomarker+testing+in+colorectal+carcinoma+%28CRC%29%3A+a+national+consensus+of+the+Spanish+Society+of+Pathology+%28SEAP%29+and+the+Spanish+Society+of+Medical+Oncology+%28SEOM%29&rft.jtitle=Clinical+%26+translational+oncology&rft.au=Garc%C3%ADa-Alfonso%2C+Pilar&rft.au=Salazar%2C+Ram%C3%B3n&rft.au=Garc%C3%ADa-Foncillas%2C+Jes%C3%BAs&rft.au=Musul%C3%A9n%2C+Eva&rft.date=2012-10-01&rft.pub=Springer+Milan&rft.issn=1699-048X&rft.eissn=1699-3055&rft.volume=14&rft.issue=10&rft.spage=726&rft.epage=739&rft_id=info:doi/10.1007%2Fs12094-012-0856-5&rft.externalDocID=10_1007_s12094_012_0856_5
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1699-048X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1699-048X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1699-048X&client=summon